Deciphera Pharmaceuticals Inc (Deciphera Pharmaceuticals) is a research and development company that develops, designs and commercializes kinase-inhibiting drugs. The company provides a clinical pipeline of kinase inhibitors such as tumor-targeted therapies and immuno-targeted therapies. It uses proprietary switch control inhibitor platform for discovering and developing kinase inhibitors. Deciphera Pharmaceuticals products are used in the treatment of renal and colon cancers, mastocytosis, gastrointestinal stromal tumors, Crohn’s disease and autoimmune nephritis, solid tumors and rheumatoid arthritis. The company's products are used in the treatment of immunological diseases and cancers. It markets its products through medical representatives. Deciphera Pharmaceuticals is headquartered in Waltham, Massachusetts, the US
Headquarters
United States of America
Address
200 Smith St, Waltham, Massachusetts, 02451-0099
Website
www.deciphera.com
Telephone
1 781 2096400
No of Employees
355
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
DCPH (NASD)
Revenue (2022)
$163.4M
21.9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-8.9%
(2022 vs 2021)
Market Cap*
$1.2B
Net Profit Margin (2022)
XYZ
10.6%
(2022 vs 2021)
* As of and is in US$
Deciphera Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Ripretinib |
| Vimseltinib |
| DCC-3116 |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In January, the company entered into an agreement with GENESIS Pharma to commercialize RIPRETINIB in 14 European markets to treat fourth-line gastrointestinal stromal tumors. |
| 2022 | Contracts/Agreements | In February, the company and Clinigen Group plc signed a distribution agreement for the supply and distribution of QINLOCK (ripretinib) into multiple countries across the globe. |
| 2021 | Others | In November, the company announced a corporate restructuring to prioritize clinical development programs to focus on discovery research. |
Competitor Comparison
| Key Parameters | Deciphera Pharmaceuticals Inc | Eurofins AvTech Laboratories Inc | BioNTech US Inc | Biothera | Delmont Laboratories Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Waltham | East Lansing | Cambridge | Eagan | Swarthmore |
| State/Province | Massachusetts | Michigan | Massachusetts | Minnesota | Pennsylvania |
| No. of Employees | 355 | - | 71 | - | - |
| Entity Type | Public | Private | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| James A. Bristol, Ph.D. | Chairman | Executive Board | 2007 | - |
| Steven L. Hoerter | President; Director; Chief Executive Officer | Executive Board | 2019 | - |
| Tucker Kelly | Chief Financial Officer; Executive Vice President; Treasurer | Senior Management | - | - |
| Stephen B. Ruddy, Ph.D. | Chief Technology Officer; Senior Vice President | Senior Management | 2018 | - |
| Matthew L. Sherman | Chief Medical Officer; Executive Vice President | Senior Management | 2019 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward